Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Dexamethasone Phosphate 4 mg/ml Solution for Injection
Medicines register · Ireland

Dexamethasone Phosphate 4 mg/ml Solution for Injection

Authorisation PA0822/201/001 · Pfizer Healthcare Ireland Unlimited Company

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 21 Nov 2026
Licence holder
Pfizer Healthcare Ireland Unlimited Company (all products →)
Active substance
Dexamethasone sodium phosphate
Clinical trials
344 clinical trials →
Dosage form
Solution for injection
Route of administration
Intravenous use
ATC codes
H02AB, H02AB02
First authorised
28/07/1986
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Dexamethasone sodium phosphate: supply and approvals

22 authorised products on the HPRA list contain Dexamethasone sodium phosphate. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
Dexamethasone Sodium Phosphate Injection: in shortage, updated 18 Nov 2026
Germany (BfArM)
1 supply notice, e.g. Dexamethason 1,5 mg Jenapharm (1 Jun 2026 to 29 Jan 2027)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 40 years (since 28 July 1986). The HPRA list marks it as marketed in Ireland.

Other medicines with Dexamethasone sodium phosphate in Ireland

10 other products on the HPRA list contain Dexamethasone sodium phosphate, from 10 licence holders; 4 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Dexamethasone Phosphate Krka 4 mg/ml solution for injection/infusionKRKA, d.d., Novo mestoNational authorisation (PA)Marketed
Dexamethasone phosphate Noridem 4 mg/mL Solution for injectionNoridem Enterprises LimitedNational authorisation (PA)Marketed
Dexamethasone phosphate Teva 4 mg/ml solution for injectionTeva B.V.National authorisation (PA)Marketed
Dexsol 2 mg/ 5 ml Oral SolutionTaw Pharma (Ireland) LimitedNational authorisation (PA)Marketed
Dexamethasone Phosphate 4 mg/ml solution for injectionhameln pharma GmbHNational authorisation (PA)Not marketed
Dexamethasone phosphate 4 mg/ml solution for injectionFresenius Kabi Deutschland GmbHNational authorisation (PA)Not marketed
Dexamethasone phosphate 4 mg/ml solution for injection/infusionAS KalceksNational authorisation (PA)Not stated
Dexamethasone phosphate 4mg/ml Solution for Injection or InfusionPinewood Laboratories LimitedNational authorisation (PA)Not marketed
Dexeta 1.37 mg/ml eye drops, solution in single dose containerSIFI S.p.A.National authorisation (PA)Not marketed
Dexliq 4 mg/ml Oral SolutionLaboratoires CTRSNational authorisation (PA)Not marketed

Other substances in ATC group H02AB

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 8 other active substances share the group H02AB with this product:

Hydrocortisone (9) · Prednisolone (6) · Methylprednisolone acetate (4) · Methylprednisolone (4) · Dexamethasone (2) · Lidocaine hydrochloride (1) · Dexamethasone acetate (1) · Hydrocortisone sodium phosphate (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Pfizer Healthcare Ireland Unlimited Company holds 109 products on the HPRA list, with 63 different active substances; 104 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.